Osteoarthritis Pain – Pipeline Review, H2 2015

“Osteoarthritis Pain – Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Osteoarthritis Pain – Pipeline Review, H2 2015’, provides an overview of the Osteoarthritis Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain
– The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects
– The report summarizes all the dormant and discontinued pipeline projects
– A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– A detailed assessment of monotherapy and combination therapy pipeline projects
– Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type
– Latest news and deals relating related to pipeline products

Reasons to buy

– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Develop strategic initiatives by understanding the focus areas of leading companies
– Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain
– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
– Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”

“Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Osteoarthritis Pain Overview 8
Therapeutics Development 9
Pipeline Products for Osteoarthritis Pain – Overview 9
Pipeline Products for Osteoarthritis Pain – Comparative Analysis 10
Osteoarthritis Pain – Therapeutics under Development by Companies 11
Osteoarthritis Pain – Therapeutics under Investigation by Universities/Institutes 15
Osteoarthritis Pain – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Osteoarthritis Pain – Products under Development by Companies 20
Osteoarthritis Pain – Products under Investigation by Universities/Institutes 24
Osteoarthritis Pain – Companies Involved in Therapeutics Development 25
AbbVie Inc. 25
Addex Therapeutics Ltd 26
Afferent Pharmaceuticals, Inc. 27
Akron Molecules AG 28
Allergan Plc 29
Amgen Inc. 30
Ampio Pharmaceuticals, Inc. 31
AnaMar AB 32
Antibe Therapeutics, Inc. 33
AskAt Inc. 34
Astellas Pharma Inc. 35
AstraZeneca Plc 36
Boehringer Ingelheim GmbH 37
Bone Medical Limited 38
Centrexion Corporation 39
Convergence Pharmaceuticals Ltd. 40
Eli Lilly and Company 41
Elite Pharmaceuticals, Inc. 42
Flexion Therapeutics, Inc. 43
Grunenthal GmbH 44
Iroko Pharmaceuticals, LLC 45
Nektar Therapeutics 46
Nuvo Research Inc. 47
Pfizer Inc. 48
Phosphagenics Limited 49
Pozen, Inc. 50
Purdue Pharma L.P. 51
Regeneron Pharmaceuticals, Inc. 52
Rottapharm SpA 53
Osteoarthritis Pain – Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Target 56
Assessment by Mechanism of Action 59
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
(lidocaine hydrochloride + tetracaine hydrochloride) – Drug Profile 66
(naltrexone hydrochloride + oxycodone hydrochloride) SR – Drug Profile 68
A-889425 – Drug Profile 70
AAT-008 – Drug Profile 71
ADX-71441 – Drug Profile 72
AF-219 – Drug Profile 73
AKR-202 – Drug Profile 75
AMAP-102 – Drug Profile 76
Ampion – Drug Profile 78
AQU-010 – Drug Profile 80
AS-288640100 – Drug Profile 81
ATB-346 – Drug Profile 82
BI-1026706 – Drug Profile 84
calcitonin – Drug Profile 85
capsaicin – Drug Profile 87
cebranopadol – Drug Profile 89
celecoxib – Drug Profile 91
CGS-125 – Drug Profile 92
CR-4056 – Drug Profile 93
CRB-0022 – Drug Profile 94
CRB-0089 – Drug Profile 95
duloxetine hydrochloride DR – Drug Profile 96
ELS-130 – Drug Profile 98
fasinumab – Drug Profile 99
fulranumab – Drug Profile 101
FX-005 – Drug Profile 104
grapiprant – Drug Profile 105
ibuprofen – Drug Profile 107
MEDI-7352 – Drug Profile 108
naproxen sodium – Drug Profile 109
NEO-5024 – Drug Profile 111
NEO-6860 – Drug Profile 112
NKTR-181 – Drug Profile 113
OLT-1177 – Drug Profile 115
onabotulinumtoxin A – Drug Profile 116
oxycodone ER – Drug Profile 119
PA-300 DR – Drug Profile 121
PA-65020 – Drug Profile 122
Small Molecule to Agonize TRPV1 for Osteoarthritic Pain – Drug Profile 123
Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain – Drug Profile 124
Small Molecules to Agonize TRPV1 for Osteoarthritis Pain – Drug Profile 125
Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain – Drug Profile 126
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain – Drug Profile 127
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation – Drug Profile 128
Small Molecules to Inhibit PDE2 for Osteoarthritis Pain – Drug Profile 129
tanezumab – Drug Profile 130
triamcinolone acetonide sodium phosphate SR – Drug Profile 133
V-116517 – Drug Profile 135
VG-201 – Drug Profile 136
VLNX-4975 – Drug Profile 137
Osteoarthritis Pain – Recent Pipeline Updates 138
Osteoarthritis Pain – Dormant Projects 170
Osteoarthritis Pain – Discontinued Products 175
Osteoarthritis Pain – Product Development Milestones 177
Featured News & Press Releases 177
Appendix 185
Methodology 185
Coverage 185
Secondary Research 185
Primary Research 185
Expert Panel Validation 185
Contact Us 185
Disclaimer 186″
“List of Tables
Number of Products under Development for Osteoarthritis Pain, H2 2015 13
Number of Products under Development for Osteoarthritis Pain – Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 16
Number of Products under Development by Companies, H2 2015 (Contd..1) 17
Number of Products under Development by Companies, H2 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2015 19
Comparative Analysis by Late Stage Development, H2 2015 20
Comparative Analysis by Clinical Stage Development, H2 2015 21
Comparative Analysis by Early Stage Development, H2 2015 22
Comparative Analysis by Unknown Stage Development, H2 2015 23
Products under Development by Companies, H2 2015 24
Products under Development by Companies, H2 2015 (Contd..1) 25
Products under Development by Companies, H2 2015 (Contd..2) 26
Products under Development by Companies, H2 2015 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2015 28
Osteoarthritis Pain – Pipeline by AbbVie Inc., H2 2015 29
Osteoarthritis Pain – Pipeline by Addex Therapeutics Ltd, H2 2015 30
Osteoarthritis Pain – Pipeline by Afferent Pharmaceuticals, Inc., H2 2015 31
Osteoarthritis Pain – Pipeline by Akron Molecules AG, H2 2015 32
Osteoarthritis Pain – Pipeline by Allergan Plc, H2 2015 33
Osteoarthritis Pain – Pipeline by Amgen Inc., H2 2015 34
Osteoarthritis Pain – Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 35
Osteoarthritis Pain – Pipeline by AnaMar AB, H2 2015 36
Osteoarthritis Pain – Pipeline by Antibe Therapeutics, Inc., H2 2015 37
Osteoarthritis Pain – Pipeline by AskAt Inc., H2 2015 38
Osteoarthritis Pain – Pipeline by Astellas Pharma Inc., H2 2015 39
Osteoarthritis Pain – Pipeline by AstraZeneca Plc, H2 2015 40
Osteoarthritis Pain – Pipeline by Boehringer Ingelheim GmbH, H2 2015 41
Osteoarthritis Pain – Pipeline by Bone Medical Limited, H2 2015 42
Osteoarthritis Pain – Pipeline by Centrexion Corporation, H2 2015 43
Osteoarthritis Pain – Pipeline by Convergence Pharmaceuticals Ltd., H2 2015 44
Osteoarthritis Pain – Pipeline by Eli Lilly and Company, H2 2015 45
Osteoarthritis Pain – Pipeline by Elite Pharmaceuticals, Inc., H2 2015 46
Osteoarthritis Pain – Pipeline by Flexion Therapeutics, Inc., H2 2015 47
Osteoarthritis Pain – Pipeline by Grunenthal GmbH, H2 2015 48
Osteoarthritis Pain – Pipeline by Iroko Pharmaceuticals, LLC, H2 2015 49
Osteoarthritis Pain – Pipeline by Nektar Therapeutics, H2 2015 50
Osteoarthritis Pain – Pipeline by Nuvo Research Inc., H2 2015 51
Osteoarthritis Pain – Pipeline by Pfizer Inc., H2 2015 52
Osteoarthritis Pain – Pipeline by Phosphagenics Limited, H2 2015 53
Osteoarthritis Pain – Pipeline by Pozen, Inc., H2 2015 54
Osteoarthritis Pain – Pipeline by Purdue Pharma L.P., H2 2015 55
Osteoarthritis Pain – Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 56
Osteoarthritis Pain – Pipeline by Rottapharm SpA, H2 2015 57
Assessment by Monotherapy Products, H2 2015 58
Assessment by Combination Products, H2 2015 59
Number of Products by Stage and Target, H2 2015 61
Number of Products by Stage and Mechanism of Action, H2 2015 64
Number of Products by Stage and Route of Administration, H2 2015 67
Number of Products by Stage and Molecule Type, H2 2015 69
Osteoarthritis Pain Therapeutics – Recent Pipeline Updates, H2 2015 142
Osteoarthritis Pain – Dormant Projects, H2 2015 174
Osteoarthritis Pain – Dormant Projects (Contd..1), H2 2015 175
Osteoarthritis Pain – Dormant Projects (Contd..2), H2 2015 176
Osteoarthritis Pain – Dormant Projects (Contd..3), H2 2015 177
Osteoarthritis Pain – Dormant Projects (Contd..4), H2 2015 178
Osteoarthritis Pain – Discontinued Products, H2 2015 179
Osteoarthritis Pain – Discontinued Products (Contd..1), H2 2015 180″
“List of Figures
Number of Products under Development for Osteoarthritis Pain, H2 2015 13
Number of Products under Development for Osteoarthritis Pain – Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 19
Comparative Analysis by Clinical Stage Development, H2 2015 21
Comparative Analysis by Early Stage Products, H2 2015 22
Assessment by Monotherapy Products, H2 2015 58
Assessment by Combination Products, H2 2015 59
Number of Products by Top 10 Targets, H2 2015 60
Number of Products by Stage and Top 10 Targets, H2 2015 60
Number of Products by Top 10 Mechanism of Actions, H2 2015 63
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 63
Number of Products by Routes of Administration, H2 2015 66
Number of Products by Stage and Routes of Administration, H2 2015 66
Number of Products by Molecule Types, H2 2015 68
Number of Products by Stage and Molecule Types, H2 2015 68″